Dr. Clincy Cheung obtained his PhD in Materials Science and Engineering from UCLA. This episode is a layman’s introduction to radiopharmaceuticals, a class of radioactive drugs with transformative implications to cancer diagnosis and treatment. 

Besides the science and applications of radiopharmaceuticals, we also discussed their production process, key players, and recent industry trends. The most interesting revelation came when Clincy brought up how unlike most of the traditional pharm supply chains, the radiopharmaceutical value chain is very much dictated by the "half-life" of the radioactive compounds. In other words, it is a business “at the mercy of physics”.

DISCLAIMER. The content provided is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Timestamps
(00:00:00) Introduction
(00:03:29) Cancer and Radiopharma Overview
(00:09:10) History of Radiopharma Science
(00:14:07) Development of PET Scans
(00:18:49) Radiopharma Compounds
(00:23:32) Industry Landscape & Production Process
(00:27:22) Radioactive Decay
(00:33:49) Supply Chain & Unit Economics
(00:43:59) Regulatory Regimes
(00:48:55) Cost of Different Treatments
(00:50:33) The Future of Radiopharma

Disclaimer: This podcast is an independent personal project and is not affiliated with or endorsed by any employer or organization. All views expressed are solely those of the host and guests. The content is for information and entertainment purposes only and does not constitute financial, investment, legal, tax, or professional advice. The host, guests, and associated parties assume no liability for any actions taken based on this content.